ArticleTheranostics2025
CRISPR screening reveals ZNF217 as a vulnerability in high-risk B-cell acute lymphoblastic leukemia.
Abstract read
In one paragraph
Article in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The transcription factor ZNF217 drives hepatocellular carcinoma progression by activating de novo lipid synthesis via FASN upregulation.Journal of cancer research and clinical oncology · 2026Article
- Ex vivo long-term expansion of human hematopoietic stem and progenitor cells as a tool for modeling vector integration sites and clonality.Journal of translational medicine · 2026Article
- Zinc finger protein 514 promotes esophageal cancer progression by enhancing cell proliferation, migration and invasion.Molecular medicine reports · 2026Article
- NSUN2 promotes leukemogenesis by ferritin heavy chain 1-mediated anti-ferroptosis and enhancing global protein synthesis in an mClinical epigenetics · 2025Article
- Advances in the application of patient-derived xenograft models in acute leukemia resistance.Cancer drug resistance (Alhambra, Calif.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Xi QinDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Keren ZhouDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Lei DongDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Lu YangDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Wei LiDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Zhenhua ChenDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Chao ShenDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Li HanDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Yangchan LiDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Anthony K N ChanDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Sheela Pangeni PokharelDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Ying QingDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Meiling ChenDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Kitty WangDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Keith LeungDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Lillian SauDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Chun-Wei ChenDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Xiaolan DengDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Rui SuDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Jianjun ChenDepartment of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Funding
Project 2U54CA285116 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI ERNEST MARTINEZ, RUI SU · 2023 to 2026
$6.8MThe role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemiaR01CA271497 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Jianjun Chen · 2022 to 2026
$2.8MTargeting FTO to treat acute myeloid leukemiaR01CA243386 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2024
$2.8MCombinational Targeting the Feed-forward Epigenetic Circuitry in Mixed Lineage LeukemiaR37CA233691 · NCI · MAYO CLINIC ROCHESTER · PI CHEN, CHUN-WEI DAVID · 2019 to 2025
$2.8MTET2-mediated epitranscriptomic regulation in leukemia microenvironmentR01CA280389 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Jianjun Chen · 2023 to 2026
$2.7MThe role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AMLR01CA236399 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2019 to 2023
$2.3MThe function and underlying mechanism of TET1 in myelodysplastic syndromesR01DK124116 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2023
$2.2MMechanism and therapeutic opportunities of targeting the Tudor domainR01CA278050 · NCI · MAYO CLINIC ROCHESTER · PI Chun-Wei David Chen · 2023 to 2026
$2.0MThe role, mechanism, and therapeutic potential of METTL1 in acute myeloid leukemiaR37CA292678 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI RUI SU · 2024 to 2026
$1.3MNCI NIH HHS R01 CA236399NCI NIH HHS R01 CA243386NCI NIH HHS R01 CA271497NCI NIH HHS R01 CA278050NCI NIH HHS R01 CA280389NCI NIH HHS R37 CA233691NCI NIH HHS R37 CA292678NCI NIH HHS U54 CA285116NIDDK NIH HHS R01 DK124116
Abstract
PubMed holds no abstract for this paper.
Indexed as
CRISPR-Cas SystemsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaTrans-ActivatorsAnimalsCell Line, TumorCell SurvivalFusion Proteins, bcr-ablHumansMiceXenograft Model Antitumor AssaysFusion Proteins, bcr-ablTrans-ActivatorsB-cell acute lymphoblastic leukemia (B-ALL)CoRESTCRISPR-Cas9 screenFOSZNF217
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.